520 results on '"Irani, Jacques"'
Search Results
2. Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failure
3. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study
4. BCG MEDAC® for the treatment of non-muscle invasive bladder tumors: Adverse events and predictive factors for tolerance
5. Réhabilitation améliorée après cystectomie radicale
6. Developing a Diagnostic Multivariable Prediction Model for Urinary Tract Cancer in Patients Referred with Haematuria: Results from the IDENTIFY Collaborative Study
7. Efficacy and toxicity following salvage high-dose-rate brachytherapy for locally recurrent prostate cancer after radiotherapy
8. Pre-transplant morphometry by computed tomography scan and post-transplant dialysis risk in overweight or obese kidney transplant recipients
9. BCG-unresponsive high-grade non-muscle invasive bladder cancer: what does the practicing urologist need to know?
10. Prognostic Impact of pT3 Subclassification in a Multicentre Cohort of Patients with Urothelial Carcinoma of the Renal Pelvicalyceal System Undergoing Radical Nephroureterectomy: A Propensity Score-weighted Analysis After Central Pathology Review
11. Surgical complications risk in obese and overweight recipients for kidney transplantation: a predictive morphometric model based on sarcopenia and vessel-to-skin distance
12. Treatment of High-grade Non–muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial “NIMBUS”
13. EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)
14. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study
15. Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature
16. Ultrasound Molecular Imaging of Renal Cell Carcinoma: VEGFR targeted therapy monitored with VEGFR1 and FSHR targeted microbubbles
17. Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art
18. Is CIS a Contraindication to Hyperthermic Intravesical Chemotherapy (HIVEC) after BCG-Failure?
19. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: Association with tumor progression
20. 8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy
21. Diagnostic et prise en charge des événements indésirables sévères survenant au décours des instillations endovésicales de BCG pour le traitement des tumeurs de vessie n’infiltrant pas le muscle (TVNIM)
22. Is an Extended 20-Core Prostate Biopsy Protocol More Efficient than the Standard 12-Core? A Randomized Multicenter Trial
23. Prognostic Interest in Discriminating Muscularis Mucosa Invasion (T1a vs T1b) in Nonmuscle Invasive Bladder Carcinoma: French National Multicenter Study with Central Pathology Review
24. [Complications of radical nephrectomy and partial nephrectomy: What are they? How can they be anticipated and managed?]
25. Final results of the phase III URO-BCG 4 multicenter study: efficacy and tolerance of one-third dose BCG maintenance in nonmuscle invasive bladder cancer
26. Clinical Evaluation of the PCA3 Assay in Guiding Initial Biopsy Decisions
27. Risk stratification of metastatic recurrence in invasive upper urinary tract carcinoma after radical nephroureterectomy without lymphadenectomy
28. External Validation of Urinary PCA3-Based Nomograms to Individually Predict Prostate Biopsy Outcome
29. Testosterone Measurement in Patients with Prostate Cancer
30. Deuxième résection à un mois (rerésection) dans les tumeurs de vessie T1 de haut grade
31. Is Shared Decision Making in Prostate Cancer Restrained by Evidence-Based Medicine?
32. Androgen-Deprivation Therapy in Prostate Cancer: A European Expert Panel Review
33. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial
34. Expression of Estrogen Related Proteins in Hormone Refractory Prostate Cancer: Association With Tumor Progression
35. The European Association of Urology (EAU) Guidelines Methodology: A Critical Evaluation
36. MP7-05 PROGNOSTIC VALUE OF THE PT3 SUBCLASSIFICATION FOR UPPER TRACT UROTHELIAL CARCINOMAS OF THE RENAL PELVICALYCEAL SYSTEM
37. Hormone Therapy for Prostate Cancer: Exploring Current Controversies
38. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non–muscle-invasive bladder cancer
39. Adherence to Treatment Guidelines and Associated Survival in Older Patients with Prostate Cancer: A Prospective Multicentre Cohort Study
40. Place de la surveillance active dans le cancer de la prostate : présentation du protocole français: Active surveillance in prostate cancer: the French protocol
41. Continuous versus Six Months a Year Maximal Androgen Blockade in the Management of Prostate Cancer: A Randomised Study
42. Highlights on Prostate Cancer from Urological and Oncological Congresses in 2007
43. What is New in Bladder Cancer Diagnosis and Management?
44. Prise en charge des carcinomes Ta, T1, et in situ de vessie : quoi de neuf ?
45. Efficacy and tolerance of one-third full dose bacillus Calmette–Guérin maintenance therapy every 3 months or 6 months: Two-year results of URO-BCG-4 multicenter study
46. ERG expression in prostate cancer: The prognostic paradox
47. Is intermittent androgen-deprivation therapy beneficial for patients with advanced prostate cancer?
48. Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer?
49. Oncological risk of laparoscopic surgery in urothelial carcinomas
50. The IDENTIFY Study: The Investigation and Detection of Urological Neoplasia in Patients Referred with Suspected Urinary Tract Cancer; A multicentre observational study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.